Relmada Therapeutics (RLMD) Other financing activities (2014 - 2026)

Relmada Therapeutics (RLMD) has 8 years of Other financing activities data on file, last reported at $160.0 million in Q1 2026.

• On a quarterly basis, Other financing activities changed N/A year-over-year to $160.0 million in Q1 2026; TTM through Mar 2026 was $160.0 million, a N/A change from a year earlier, with the FY2024 full-year figure at $246747.0, up 150.6% from the prior year.
• Other financing activities for Q1 2026 stood at $160.0 million, up from $246747.0 in the prior quarter.
• Over the last five years, Other financing activities for RLMD reached as high as $160.0 million in Q1 2026 and fell as low as -$191636.0 in Q3 2022.
• Historically, Other financing activities has averaged $32.2 million across 3 years, with a median of $300006.0 in 2022.
• On a YoY basis, Other financing activities climbed as much as 163.12% in 2022 and fell as far as 111.98% in 2022.
• Year by year, Other financing activities stood at -$191636.0 in 2022, then surged by 228.76% to $246747.0 in 2024, then soared by 64743.75% to $160.0 million in 2026.
• Per Business Quant data, the three most recent Other financing activities figures were $160.0 million in Q1 2026, $246747.0 in Q1 2024, and -$191636.0 in Q3 2022.